Experiences and opportunities for efferent treatment of COVID-19 convalescent plasma
- VernacularTitle:Коронавирүст халдвар (COVID-19)-ын дархлаажсан сийвэнг (ИЙЛДЭС) эфферент эмчилгээний туршлага, боломж
- Author:
Yunden S
1
;
Davaadorj R
2
;
Ulziisaikhan T
3
;
Och G
2
;
Chimgee L
4
Author Information
1. Ministry of Health
2. National Center for Public Health
3. National Toxicilogy Emergency Center
4. Mongolian National University of Medical Sciences
- Publication Type:Review
- Keywords:
COVID-19;
Convalescent plasma;
Efferent treatment
- From:Mongolian Medical Sciences
2020;192(2):60-65
- CountryMongolia
- Language:Mongolian
-
Abstract:
According to international medical organizations, the use of efferent therapy that COVID-19
convalescent plasma has shown some results.
Convalescent plasma that contains antibodies to severe acute respiratory syndrome coronavirus 2 or
SARS-CoV-2. This is being studied for administration to patients with COVID-19. Use of convalescent
plasma has been studied in outbreak of other respiratory infections, including the 2003 SARS-CoV-1,
the 2009-2010 H1N1 influenza virus, and the 2012 MERS-CoV.
Although promising, convalescent plasma has not yet been shown to be safety and efficacy of
COVID-19 convalescent plasma in clinical trials.
Plasmapheresis and membrane plasmapheresis of efferent therapy has been used in clinical
toxicology since 1995, in Mongolia.
- Full text:2020-192(2)-60-65.pdf
